On 2016 Jun 24, Erick H Turner commented:

I am the author of the NEJM article cited as reference #17, in which we showed stark differences in antidepressant efficacy according to two data sources–published journal articles and FDA reviews. The authors of this BMJ Open protocol list a number of sources they plan to search. What is not clear is how what they plan to do when faced with results of the same clinical trial from two (or more) sources. In our NEJM article, we found 11 trials which were positive according to journal articles but negative according to the FDA. When one considers that those journal articles were authored by those with a conflict of interest, and that the discrepancies were due to post hoc outcome switching, it seems clear that FDA reviews should be prioritized as the more credible data source.

On 2016 Jun 24, Erick H Turner commented:

I am the author of the NEJM article cited as reference #17, in which we showed stark differences in antidepressant efficacy according to two data sources–published journal articles and FDA reviews. The authors of this BMJ Open protocol list a number of sources they plan to search. What is not clear is how what they plan to do when faced with results of the same clinical trial from two (or more) sources. In our NEJM article, we found 11 trials which were positive according to journal articles but negative according to the FDA. When one considers that those journal articles were authored by those with a conflict of interest, and that the discrepancies were due to post hoc outcome switching, it seems clear that FDA reviews should be prioritized as the more credible data source.